Welcome to our dedicated page for Arcus Bioscience news (Ticker: RCUS), a resource for investors and traders seeking the latest updates and insights on Arcus Bioscience stock.
Arcus Biosciences, Inc. (NYSE: RCUS) generates frequent news as a clinical-stage, global biopharmaceutical company advancing investigational therapies for cancer, inflammatory diseases and autoimmune diseases. News about Arcus often centers on clinical trial updates for its lead programs, collaboration developments and corporate financing activities that support its pipeline.
Key oncology news items include data readouts and study milestones for casdatifan, a small-molecule HIF‑2α inhibitor being developed for clear cell renal cell carcinoma (ccRCC). Investors can follow announcements from the ARC‑20 Phase 1/1b study in late-line and early-line ccRCC, the global Phase 3 PEAK‑1 trial in immunotherapy-experienced metastatic ccRCC, and the eVOLVE‑RCC02 Phase 1b/3 study that combines casdatifan with volrustomig in first-line metastatic ccRCC. Updates often highlight progression-free survival, response rates, safety findings and the design of new cohorts or registrational strategies.
Arcus news also covers its broader oncology portfolio, including quemliclustat, a CD73 inhibitor in the PRISM‑1 Phase 3 trial for first-line metastatic pancreatic ductal adenocarcinoma, and the domvanalimab plus zimberelimab combinations in gastrointestinal and lung cancers. Coverage has included positive survival and response data from the Phase 2 EDGE‑Gastric study, as well as the later decision to discontinue the Phase 3 STAR‑221 and EDGE‑Gastric studies after an interim analysis showed no overall survival benefit over standard therapy.
On the inflammation and immunology side, Arcus issues updates on its emerging small-molecule programs targeting MRGPRX2, TNF, CCR6 and CD40L, and an anti‑CD89 antibody program. News may describe preclinical progress, selection of development candidates and plans to enter the clinic in indications such as atopic dermatitis, chronic spontaneous urticaria, rheumatoid arthritis, psoriasis, inflammatory bowel disease, multiple sclerosis and systemic lupus erythematosus.
Corporate and financial news for RCUS includes public equity offerings, amendments to loan facilities, participation in major healthcare and investor conferences, and guidance on cash runway. Readers can use this news page to follow how clinical data, partnership decisions with Gilead Sciences and Taiho Pharmaceutical, and capital-raising activities shape Arcus’s development priorities over time.
Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company specializing in cancer therapies, has announced new employment inducement grants. The company's Compensation Committee has approved equity awards for twelve new employees, consisting of:
- Options to purchase 42,920 shares of common stock at $9.12 per share (closing price on March 24, 2025)
- Restricted stock units (RSUs) for 21,650 shares of common stock
These equity awards were granted under the company's 2020 Inducement Plan, which was established in January 2020 under the NYSE Listed Company Manual Rule 303A.08 inducement exception.
Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company specializing in cancer therapeutics, has announced its participation in two major healthcare investor conferences in March 2025.
The company will attend the Leerink Global Healthcare Conference on March 12th, 2025, and the Barclays 27th Annual Global Healthcare Conference on March 13th, 2025. Both events will take place in Miami Beach, FL, featuring fireside chats and one-on-one meetings scheduled for 8:00 a.m. ET.
Investors can access live webcasts of these presentations through the Investors & Media section of www.arcusbio.com, with replay options available after the events.
Arcus Biosciences (NYSE:RCUS) has reported its Q4 and full-year 2024 financial results, highlighting significant progress in its cancer therapy pipeline. The company's lead drug casdatifan showed promising results in Phase 1/1b ARC-20 study for clear cell renal cell carcinoma (ccRCC), with over 30% confirmed overall response rate in two cohorts and favorable safety profile.
Key financial metrics include:
- Cash position of $992 million as of December 31, 2024
- Q4 2024 revenues of $36 million
- R&D expenses increased to $111 million in Q4 2024
- Net loss of $94 million in Q4 2024
The company plans to initiate the Phase 3 PEAK-1 study evaluating casdatifan with cabozantinib in H1 2025, with initial combination data expected mid-2025. Arcus completed a $150 million financing and expects current funding to support pivotal trials through initial readouts.
Arcus Biosciences (NYSE:RCUS) announced that its Compensation Committee has granted equity awards to one new employee. The grants include options to purchase 5,550 shares of common stock at an exercise price of $11.07 per share, which matched the closing price on February 21, 2025. Additionally, the employee received restricted stock units to acquire 2,800 shares of common stock. These equity awards were issued under the company's 2020 Inducement Plan, which was established in January 2020 under the NYSE Listed Company Manual Rule 303A.08's 'inducement exception'.
Arcus Biosciences (NYSE:RCUS) has retained full rights to casdatifan, a HIF-2a inhibitor for clear cell renal cell carcinoma (ccRCC), following the expiration of Gilead Sciences' option window. The company has also priced a $150 million common stock offering with participation from new and existing investors, including Gilead.
New data from the ARC-20 study showed improvements in progression rates, overall response rate (ORR), and progression-free survival (PFS) for casdatifan monotherapy. The company estimates a $5 billion market opportunity for this treatment. Key upcoming milestones include the initiation of the Phase 3 PEAK-1 trial in Q2 2025 and a clinical collaboration with AstraZeneca to evaluate casdatifan in combination with their anti-PD-1/CTLA-4 bispecific antibody.
Arcus Biosciences (NYSE:RCUS) has announced the pricing of an underwritten public offering of 13,636,364 shares of common stock at $11.00 per share, aiming to raise approximately $150 million in gross proceeds. The offering is expected to close around February 19, 2025.
The company plans to use the net proceeds to fund ongoing research and development activities, including the clinical development of casdatifan, manufacturing-related costs, and other general corporate purposes. Goldman Sachs, Leerink Partners, and Evercore ISI are serving as joint book-running managers for the offering.
Arcus Biosciences (NYSE:RCUS) presented new data for casdatifan, their HIF-2a inhibitor for metastatic kidney cancer, showing promising results across three monotherapy cohorts. The 50mg twice-daily cohort achieved a 9.7-month median progression-free survival, while other cohorts had not yet reached their median.
Key findings include a 33% confirmed response rate in the 100mg cohort using tablet formulation, which is the expected go-forward dose for pivotal studies. Across all cohorts, 81-87% of patients experienced disease control with either partial response or stable disease. The study involved heavily pretreated patients, with 52-59% having received at least three prior lines of therapy.
Casdatifan demonstrated an acceptable safety profile, with low discontinuation rates. The company plans to advance the drug through multiple development programs, including the Phase 3 PEAK-1 study in combination with cabozantinib.
Arcus Biosciences (NYSE:RCUS) has announced new employment inducement grants for its recently appointed Chief Medical Officer, Dr. Richard Markus, and two new employees. Dr. Markus received an option to purchase 305,328 shares of common stock at $12.45 per share and restricted stock units for 75,193 shares. Additionally, two new employees were granted options to purchase 9,150 shares at $12.45 per share and restricted stock units for 4,600 shares. These equity awards were granted under the Company's 2020 Inducement Plan, approved under NYSE Listed Company Manual Rule 303A.08's inducement exception.
Arcus Biosciences (NYSE:RCUS) announced upcoming presentation of new data from their ARC-20 study at the 2025 ASCO GU Symposium. The presentation will showcase safety and efficacy data for casdatifan, their HIF-2a inhibitor, in treating clear cell renal cell carcinoma (ccRCC).
The presentation will include initial data from the 100mg once-daily tablet cohort, which is their selected dose for Phase 3 studies, along with updated data from the 50mg twice-daily and 50mg once-daily expansion cohorts. Dr. Toni Choueiri from Dana-Farber Cancer Institute will present the findings on February 15, 2025.
Arcus is advancing casdatifan's development program, including the planned initiation of their Phase 3 study (PEAK-1) in the first half of 2025, a clinical collaboration with AstraZeneca to evaluate casdatifan in combination with volrustomig, and new cohorts to evaluate the treatment in first-line settings.
Arcus Biosciences (NYSE:RCUS) has announced new employment inducement grants approved by its Compensation Committee. The grants include stock options for 31,800 shares at an exercise price of $13.33 per share and restricted stock units for 16,000 shares of common stock. These equity awards were granted to four new employees under the company's 2020 Inducement Plan, which was established under NYSE Listed Company Manual Rule 303A.08's inducement exception. The exercise price reflects the closing price of RCUS stock on January 23, 2024.
FAQ
What is the current stock price of Arcus Bioscience (RCUS)?
What is the market cap of Arcus Bioscience (RCUS)?
